We're presenting 16 posters at AACR 2018. Preview our topics now, covering a wide variety of preclinical oncology and immuno-oncology platforms including NGS and transcriptomic PDX analysis, novel murine allograft models, as well as PBMC and humanized drug target models for immunotherapy assessment.
Validate your lead compounds with rapid and cost-effective screening of over 500 cancer cell lines.
Presented by Dr Toni Jun, this webinar introduces a one stop, integrated in vitro/ex vivo I/O assay plaform designed to effciently progress immunotherapy drug development. Learn how to monitor and assess TIL populations and functions, explore the microbiome's role in immunotherapy, and understand a wide range of functional characteristics across the I/O field including tumor microenvironment regulation.
Presented by Dr Henry Li, this webinar explores the detailed data analysis behind the industry's first large-scale, staggered, syngeneic screening platform for immunotherapy development. Learn how this platform can improve efficiency and reproducibility while reducing cost, how comprehensive immunophenotyping and profiling data is used to address key study design questions, and how RNAseq and FACS/IHC analysis are used for biomarker discovery.
Enhance your humanized mouse immuno-oncology studies through a deeper understanding of model immunological features and optimized uses. Learn more about immune system humanization strategies, and how these result in different models with contrasting features and limitations, then explore model applications through cancer pharmacology case studies.
Learn more about the world's largest patient-derived xenograft (PDX) collection. Download or request a poster today.
Hear Dr Henry Li, Vice President of Biomarker and Diagnostic Technology present our AACR-NCI-EORTC 2017 selected Short Talk titled 'Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments'
Learn how to leverage CrownBio's integrated Oncology Portfolio to advance your Target Identification studies. Watch our webinar presented by Michelle Mack.
Transform your preclinical oncology drug development, with mouse clinical trials using patient-derived xenograft (PDX) models. Learn how the different types of MCT are executed, which is the best fit for your specific drug discovery program, and how they provide the perfect framework for biomarker discovery.
Presented by Dr. Keefe Chng and Dr Judith Gorski this webinar will help guide you through a study design process that will enable the greatest opportunity to generate robust, high-quality data, that gives maximum confidence to select new drug candidates and regulatory submissions.
This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.
Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.
Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.
March 19, 2018
Immune checkpoint inhibitors (ICIs) have dramatically changed the therapeutic approach to...
March 13, 2018
The rise of immunotherapy has brought many new targets to the forefront of oncology drug...
March 7, 2018
A newly-described technique could open multiple lines of investigation into the pathophysiology...
March 19 - 21, 2018
March 28 - 29, 2018
April 9 - 11, 2018
April 14 - 18, 2018
Chicago, Illinois - Booth #3012
April 23 - 25, 2018
May 24 - 25, 2018